Risa Ebina-Shibuya

Risa Ebina-Shibuya

Auto-generated profile, based on publicly available information

Risa Ebina-Shibuya

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
RERisa Ebina-Shibuya
Risa Ebina-Shibuya
WLWarren J. Leonard
Warren J. Leonard

13 January 2021 in eLife
Verified
Journal Article
Open access
RERisa Ebina-Shibuya
Risa Ebina-Shibuya
EWErin E West
Erin E West
RSRosanne Spolski
Rosanne Spolski
PLPeng Li
Peng Li
JOJangsuk Oh
Jangsuk Oh
WLWarren J Leonard
Warren J Leonard
Thymic stromal lymphopoietin (TSLP) is a cytokine that acts directly on CD4+ T cells and dendritic cells to promote progression of asthma, atopic dermatitis, and allergic inflammation. However, a direct role for TSLP in CD8+ T-cell primary responses remains controversial and its role in memory CD8+ T cell responses to secondary viral infection is unknown. Here, we investigate the role of TSLP in both primary and recall responses in mice using two different viral systems. Interestingly, TSLP limited the primary CD8+ T-cell response to influenza but did not affect T cell function nor significantly alter the number of memory CD8+ T cells generated after influenza infection. However, TSLP inhibited memory CD8+ T-cell responses to secondary viral infection with influenza or acute systemic LCMV infection. These data reveal a previously unappreciated role for TSLP on recall CD8+ T-cell responses in response to viral infection, findings with potential translational implications.

10 May 2023 in Clinical and Translational Medicine
Verified
Journal Article
Open access
RERisa Ebina‐Shibuya
Risa Ebina‐Shibuya
WLWarren J. Leonard
Warren J. Leonard

24 September 2024 in Nature Reviews Immunology
Verified
Journal Article
Open access
PDF file
RERisa Ebina-Shibuya
Risa Ebina-Shibuya
WLWarren J. Leonard
Warren J. Leonard

1 May 2021 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
HMHiromi Matsumoto
Hiromi Matsumoto
Nobuyuki HoritaNobuyuki Horita
Nobuyuki Horita
KIKentaro Ito
Kentaro Ito
RERisa Ebina-Shibuya
Risa Ebina-Shibuya
YHYu Hara
Yu Hara
TKTakeshi Kaneko
Takeshi Kaneko
Although objective response rate and disease control rate are commonly used as primary endpoints of lung cancer trials, it remains unclear whether objective response rate and disease control rate correctly reflect the overall survival in a non-small cell lung cancer phase II trial evaluating a non-first-line chemotherapy. Objective response rate might be easily affected by chance because the small number of patients in each trial achieved complete or partial response in the phase II non-first-line setting. This study was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (UMIN000040412). Four databases were searched for eligible trials. A Spearman’s rank correlation with hazard ratio of overall survival was calculated each for odds ratio of objective response rate, difference of objective response rate (%), odds ratio of disease control rate, and difference of disease control rate (%). Of 74 eligible trials, 73 reported objective response rate and 68 reported disease control rates. Nine (12%) trials included patients with driver mutation status. Thirteen (18%) and two (3%) RCTs specifically included adenocarcinoma/non-squamous and squamous subtype of non-small cell lung cancer, respectively. The Eastern Cooperative Oncology Group performance status 0−2 (N=41, 55%) and the performance status 0-1 (N=25, 34%) were frequently used performance status criteria. The median number of patients in the two arms was 116 (interquartile range, 82–159). The correlation between trial-level odds ratio of objective response rate and hazard ratio of overall survival was weak (r=−0.29, 95% CI: −0.49 to −0.05, P=0.014). An exploratory subgroup analysis suggested that fewer responders were associated with poorer correlation. Odds ratio of disease control survival (r=−0.53, 95% CI: −0.68 to −0.32, P<0.001) had moderate rank correlations with hazard ratio of overall survival. Instead of objective response rate, disease control rate should be used as the primary endpoint in a randomized phase II trial evaluating non-first-line chemotherapy for non-small cell lung cancer.

15 December 2022 in Respiratory Investigation
Verified
Journal Article
Open access
DNDaisuke Narita
Daisuke Narita
RERisa Ebina-Shibuya
Risa Ebina-Shibuya
EMEisaku Miyauchi
Eisaku Miyauchi
YTYoko Tsukita
Yoko Tsukita
RSRyota Saito
Ryota Saito
HSHisatoshi Sugiura
Hisatoshi Sugiura
Several reports have revealed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection tends to have more severe outcomes in cancer patients. Although vaccination reduces the risk of severe disease, data on antibody titers achieved by vaccination is scarce in cancer patients. We collected 79 blood samples (69 lung cancer patients and 10 control individuals) and conducted an anti-SARS-CoV-2 antibody assay to compare the antibody titer achieved with current treatment. Sixty-eight patients (86%) received the BNT162 mRNA vaccine and 11 (14%) received the mRNA-1273 vaccine. They were categorized according to the current treatment: control individuals without cancer (cohort A), lung cancer patients who were treated with cytotoxic chemotherapy (cohort B), immunotherapy (cohort C), combination of cytotoxic chemotherapy and immunotherapy (cohort D), tyrosine kinase inhibitors (cohort E), and radiation therapy (cohort F). Among 69 lung cancer patients (cohort B–F), 57 (83%) had adenocarcinoma, and 66 (96%) had advanced-stage cancer. In the anti-SARS-CoV-2 antibody assay, the antibody titer was significantly lower in lung cancer patients than in control individuals (p = 0.01). The median antibody titers were 161 AU/ml in control individuals and 59.9 AU/ml in lung cancer patients. Antibody titers after the second vaccination were lower in cancer patients than those in healthy individuals. Our findings provide essential information for understanding the benefits and necessity of additional vaccination to prevent SARS-CoV-2 infection in lung cancer patients.